STUDY GOAL AND OBJECTIVES
This study provides a comprehensive analysis of available and emerging pharmaceutical treatments for cancer. Its aim is to provide a range of information—from detailed product analyses through industry trends—to quantify and qualify the market for pharmaceutical cancer treatments. Forecasts of product categories are provided for the worldwide prescription market. Forecasts and trends are gleaned from industry sources as well as from considered assessment of available and emerging technologies.
REASONS FOR DOING THE STUDY
Cancer remains the second-leading cause of death in the industrialized world and worldwide. As life expectancy worldwide continues to increase, so will cases of cancer. Unfortunately, effective therapeutic agents to combat cancer continue to be lacking. Further, many of the available agents act systemically and therefore have side effects that range from uncomfortable to life threatening. Recently, products have begun to emerge in this market that are specifically targeted to cancer cells or act in collaboration with the body's immune response to combat the disease. This marks a dynamic change in the way cancer is treated, and such innovative therapies will transform the cancer market during the next decade. Between 2000 and 2005, an estimated 134 new drugs (including innovative products as well as new formulations and/or indications for existing drugs) to treat cancer will be introduced. These new drugs are expected to generate a 75% increase in worldwide cancer drug sales.
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
This report provides a thorough background in the cancer drug market, offering information needed to understand the current market and to assess the emerging one. It is an invaluable tool for planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investor consultants, and anyone interested in the cancer pharmaceuticals market, its products, its industry participants, and its future.
SCOPE AND FORMAT
This report discusses four primary categories of currently available cancer agents: cytotoxics, biologics, hormones, and innovative therapies. Innovative therapies include such new products as angiogenesis inhibitors (including matrix metalloproteinase inhibitors and signal transduction inhibitors), monoclonal antibody products, photodynamic therapy, vaccines, and gene therapy. Market forecasts, extended discussions and trends are provided for these categories.
Not included in this report are drugs used to treat pain associated with cancer, to treat nausea, and/or vomiting associated with cancer treatments. Conditions such as hypercalcemia and xerostoma secondary to chemotherapy also are not discussed.
The competitive environment is examined with a special focus on how new products and technologies as well as acquisitions and mergers are likely to reshuffle the leading manufacturers in the cancer arena. Profiles are provided of current market leaders as well as companies with innovative products poised to enter the sector during the forecast period. Market figures are based on revenues at the manufacturers' level and are projected at 2000 value—that is, inflation is not computed into the projection figures.
Trends are assessed based on projected sales for new product introductions and expanding indications for existing products, increased ratios of generic products and subsequent declining prices in some categories. Also, expanded or altered usage of certain drugs and categories of agents, projected increases in the prevalence of certain cancers and the effect of new technologies and products on those currently available, among other factors.
Included in this report are forecasts by product segment from 1999 through 2005, including supporting analyses for all projections. The study is arranged to offer an overview of the cancer drug market accompanied by analyses and forecasts by product type. Selected international markets are discussed, as well as information on industry structure and the regulatory environment. Profiles of manufacturers of leading cancer agents as well as of biotechnology companies with novel products in development provide information on placement of current leading participants within the market and strategic analyses of emerging companies.
METHODOLOGY
Information to prepare this study was derived from data supplied by product managers, marketing strategists, research executives, and others at leading companies in the cardiovascular drug industry. Information was also obtained from researchers and product planners at companies that do not yet participate in this market but which have products in development that are poised to be introduced during the forecast period. Data was accessed from government agencies and regulatory bodies that monitor and/or regulate cancer and its treatment. Surveys of prescribing practices of physicians and pharmacists were reviewed to assess prescribing practices and opinions on products. Searches of secondary material such as company annual reports and 10Ks, journal articles, prospectus assessments, government resources, and data from health care institutions were also conducted.
INFORMATION SOURCES
Information to prepare this report was obtained from participating and emerging companies in the area of cancer drugs, industry analysts, and health care personnel. The National Cancer Institute (NCI), the American Cancer Society; the Centers for Disease Control and Prevention, the World Health Organization and other government agencies, literature searches, annual reports, 10Ks, and product literature also were utilized.
Report Code: HLC027A, Published: September 2001, Analyst: Lynn Gray
